A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers.
The effects of m-chlorophenylpiperazine (m-CPP) (0.5 mg/kg) on sleep architecture and behavior were examined in six healthy volunteers following a single oral dose of the drug in a randomized, double-blind, placebo-controlled study. m-CPP reduced total sleep time (TST) and sleep efficiency in all subjects. Slow-wave sleep (SWS) and rapid-eye-movement (REM) sleep were decreased and stage 1 sleep was prolonged in a majority of subjects. Prominent behavioral and psychological effects were reported in five out of six subjects following m-CPP (but not following placebo) that interfered with sleep. The sleep disruption and behavioral activation following nighttime administration of m-CPP contrasts with the sedative properties of its parent compound, trazodone, suggesting that the hypnotic effect of trazodone is not related to the agonist profile of its metabolite, m-CPP.
Lawlor
B A
BA
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029.
Newhouse
P A
PA
Balkin
T J
TJ
Molchan
S E
SE
Mellow
A M
AM
Murphy
D L
DL
Sunderland
T
T
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001143:Arousal / Q000187:drug effects; D002940:Circadian Rhythm / Q000187:drug effects*; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects
D010879:Piperazines; D011985:Receptors, Serotonin; C015068:1-(3-chlorophenyl)piperazine